Immunoprecise Historical Financial Ratios
| IPA Stock | USD 0.41 0.03 7.89% |
Immunoprecise Antibodies is lately reporting on over 94 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.41 or Invested Capital of 0.0 will help investors to properly organize and evaluate Immunoprecise Antibodies financial condition quickly.
Immunoprecise |
About Immunoprecise Financial Ratios Analysis
Immunoprecise AntibodiesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunoprecise Antibodies investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunoprecise financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunoprecise Antibodies history.
Immunoprecise Antibodies Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Immunoprecise Antibodies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunoprecise Antibodies sales, a figure that is much harder to manipulate than other Immunoprecise Antibodies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Immunoprecise Antibodies dividend as a percentage of Immunoprecise Antibodies stock price. Immunoprecise Antibodies dividend yield is a measure of Immunoprecise Antibodies stock productivity, which can be interpreted as interest rate earned on an Immunoprecise Antibodies investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Immunoprecise Antibodies' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.At present, Immunoprecise Antibodies' Average Payables is projected to decrease significantly based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 19.53, whereas Price To Sales Ratio is forecasted to decline to 0.11.
| 2020 | 2021 | 2022 | 2023 (projected) | Payables Turnover | 4.74 | 2.14 | 3.66 | 3.06 | Days Of Inventory On Hand | 68.95 | 70.33 | 82.61 | 62.63 |
Immunoprecise Antibodies fundamentals Correlations
Click cells to compare fundamentals
Immunoprecise Antibodies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunoprecise Antibodies fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 4.56 | 3.76 | 11.02 | 7.27 | 4.19 | 1.84 | |
| Ptb Ratio | 2.76 | 3.5 | 3.47 | 1.87 | 1.5 | 1.33 | |
| Days Sales Outstanding | 65.2 | 95.03 | 73.93 | 64.26 | 68.51 | 60.55 | |
| Book Value Per Share | 1.44 | 1.11 | 3.46 | 3.82 | 2.32 | 1.32 | |
| Free Cash Flow Yield | (0.0772) | (0.0372) | (0.0103) | (0.0794) | (0.25) | (0.12) | |
| Operating Cash Flow Per Share | (0.26) | (0.1) | (0.0364) | (0.5) | (0.8) | (0.17) | |
| Stock Based Compensation To Revenue | 0.0526 | 0.15 | 0.16 | 0.094 | 0.0626 | 0.0595 | |
| Capex To Depreciation | 0.29 | 0.17 | 0.38 | 0.33 | 0.22 | 0.24 | |
| Pb Ratio | 2.76 | 3.5 | 3.47 | 1.87 | 1.5 | 1.33 | |
| Ev To Sales | 4.33 | 3.89 | 8.88 | 5.85 | 4.14 | 2.26 | |
| Free Cash Flow Per Share | (0.31) | (0.14) | (0.12) | (0.57) | (0.86) | (0.22) | |
| Roic | (0.31) | (0.3) | (0.22) | (0.14) | (0.43) | (0.38) | |
| Inventory Turnover | 7.36 | 5.29 | 5.19 | 4.42 | 5.83 | 5.54 | |
| Net Income Per Share | (0.61) | (0.36) | (0.45) | (0.85) | (1.07) | (1.06) | |
| Days Of Inventory On Hand | 137.46 | 49.6 | 68.95 | 70.33 | 82.61 | 62.63 | |
| Payables Turnover | 3.53 | 4.45 | 4.74 | 2.14 | 3.66 | 3.06 | |
| Sales General And Administrative To Revenue | 0.7 | 0.57 | 0.71 | 0.88 | 0.96 | 0.64 | |
| Research And Ddevelopement To Revenue | 0.0936 | 0.0445 | 0.0317 | 0.11 | 0.59 | 0.17 | |
| Capex To Revenue | 0.059 | 0.0409 | 0.0797 | 0.0649 | 0.0723 | 0.057 | |
| Cash Per Share | 0.44 | 0.19 | 2.53 | 1.52 | 0.33 | 0.13 | |
| Pocfratio | (15.55) | (37.97) | (329.03) | (14.19) | (4.37) | (10.65) | |
| Interest Coverage | (4.72) | (2.85) | (7.71) | (37.66) | (869.7) | (724.32) | |
| Capex To Operating Cash Flow | (0.2) | (0.41) | (2.38) | (0.13) | (0.0754) | (0.33) | |
| Pfcf Ratio | (12.95) | (26.86) | (97.4) | (12.59) | (4.06) | (8.01) | |
| Days Payables Outstanding | 103.32 | 82.03 | 77.02 | 170.59 | 99.61 | 119.24 | |
| Income Quality | 0.42 | 0.28 | 0.0817 | 0.59 | 0.75 | 0.16 | |
| Roe | (0.42) | (0.33) | (0.13) | (0.22) | (0.46) | (0.8) | |
| Ev To Operating Cash Flow | (14.76) | (39.34) | (265.2) | (11.42) | (4.32) | (13.06) | |
| Pe Ratio | (8.46) | (6.55) | (10.68) | (26.9) | (8.42) | (3.26) | |
| Return On Tangible Assets | (0.65) | (0.45) | (0.14) | (0.4) | (0.96) | (0.95) | |
| Ev To Free Cash Flow | (12.29) | (27.83) | (78.5) | (10.14) | (4.02) | (9.82) | |
| Net Debt To E B I T D A | (0.47) | 0.63 | (4.24) | 26.99 | 2.29 | 0.0482 | |
| Current Ratio | 1.37 | 0.97 | 8.05 | 4.05 | 2.84 | 1.41 | |
| Tangible Book Value Per Share | 0.11 | (0.0813) | 2.62 | 1.18 | 0.31 | 0.1 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.